Breaking News

Globalfoundries to Buy IBM's Chip Unit; IBM Sees Pretax Charge $4.7 Billion
Tweet TWEET

Valeant Pharmaceuticals Announces Private Exchange Offer

MONTREAL, March 29, 2013 /CNW/ - Valeant Pharmaceuticals International, Inc. 
(NYSE: VRX and TSX: VRX) announced today that its wholly owned subsidiary 
Valeant Pharmaceuticals International (the "Company") intends to commence an 
offer to exchange (the "Exchange Offer") any and all of its outstanding $500 
million aggregate principal amount of 6.375% Senior Notes due 2020 (the 
"Existing Notes") for up to an additional $500 million aggregate principal 
amount of its 6.375% Senior Notes due 2020 (the "Exchange Notes") issued 
pursuant to the indenture, dated as of October 4, 2012 (the "Date of 
Issuance"), as supplemented, among the Company, Valeant Pharmaceuticals 
International, Inc. (the "Parent"), the guarantors named therein and The Bank 
of New York Mellon Trust Company, as trustee. 
The Exchange Notes will be guaranteed by same guarantors of the Existing 
Notes, which are the Parent and each of the Parent's subsidiaries (other than 
the Company) that is a guarantor of the Parent's senior secured credit 
facilities. The form and terms of the Exchange Notes will be substantially 
identical to the form and terms of the Existing Notes.  The Company is 
conducting this Exchange Offer in order to satisfy its obligations under the 
indenture governing the Existing Notes with the anticipated result being that 
some or all of such notes will be part of a single series of notes under one 
indenture using a single CUSIP number. 
Upon the terms and subject to the conditions of the Exchange Offer, for each 
$1,000 principal amount of Existing Notes validly tendered, and not withdrawn, 
in the Exchange Offer for the Existing Notes, eligible holders will receive 
$1,000 principal amount of Exchange Notes. 
The Exchange Offer will expire at 5:00 p.m., New York City time, on April 26, 
2013, unless extended or earlier terminated by the Company (such date and 
time, as the same may be extended or earlier terminated, the "Expiration 
Time"). Eligible holders that validly tender their Existing Notes and do not 
withdraw their tenders at or prior to 5:00 p.m., New York City time, on April 
9, 2013 (such date and time, the "Initial Expiration Time") will receive 
Exchange Notes on April 10, 2013. 
Tenders in the Exchange Offer may be validly withdrawn at any time prior to 
the Initial Expiration Time, but will thereafter be irrevocable, except as 
required by applicable securities laws. 
The Company may extend or terminate the Exchange Offer, in its sole and 
absolute discretion, and otherwise amend or modify the Exchange Offer in any 
respect, subject to applicable securities laws.  The Exchange Offer is open to 
all eligible holders of Existing Notes. 
The Exchange Notes have not been and will not be registered under the 
Securities Act of 1933, as amended (the "Securities Act") or any state 
securities laws.  The Exchange Notes may not be offered or sold in the United 
States or to any U.S. persons except pursuant to an exemption from, or in a 
transaction not subject to, the registration requirements of the Securities 
Act.  The Exchange Offer is being made, and the Exchange Notes are being 
offered, and issued only to holders of Existing Notes who are "qualified 
institutional buyers" (as defined in Rule 144A under the Securities Act) or 
institutional "accredited investors" within the meaning of Rule 501 (a)(1), 
(2), (3) or (7) of Regulation D under the Securities Act. 
This announcement shall not constitute an offer to sell or the solicitation of 
an offer to buy securities, nor shall there be any offer or sale of securities 
in any jurisdiction in which such offer, solicitation or sale would be 
unlawful prior to registration or qualification under the securities laws of 
any such jurisdiction. 
About Valeant Pharmaceuticals International, Inc.  Valeant Pharmaceuticals 
International, Inc. (NYSE/TSX: VRX) is a multinational specialty 
pharmaceutical company that develops, manufactures and markets a broad range 
of pharmaceutical products primarily in the areas of dermatology, neurology 
and branded generics.  More information about Valeant Pharmaceuticals 
International, Inc. can be found at www.valeant.com. 
Forward Looking Statements  This press release may contain forward-looking 
statements, including, but not limited to those related to the offering of 
Exchange Notes and whether or not the Company will consummate the offering.  
Forward-looking statements can generally be identified by the use of words 
such as "anticipate," "expect," "plan," "could," "may," "will," "should," 
"would," "intend," "seem," "potential," "appear," "continue," "future," 
believe," "estimate," "forecast," "project," variations of such words or other 
words that convey uncertainty of future events or outcome, although not all 
forward-looking statements contain these identifying words.  Our 
forward-looking statements are subject to known and unknown risks and 
uncertainties, many of which are outside of our control and could cause actual 
results to differ materially and adversely from those expressed or implied by 
such statements.  Those risks include, but are not limited to: our future 
economic performance, operating results, financial condition, capital 
resources or prospects; projections of revenue, expenses, income and losses, 
earnings (losses) per share, capital expenditures, dividends, growth rates or 
other financial items; market or industry trends, legal or regulatory 
developments; future events;  the anticipated effect of acquisitions, 
litigation, new (or changes to existing) laws, regulations or accounting 
principles or other matters on our business, economic performance, operating 
results, financial condition, capital resources or prospects; our plans, 
objectives and strategies for future operations or otherwise; and our 
expectations and beliefs.  Information concerning potential factors that could 
affect the Company's financial results is included in its Parent's most recent 
annual or quarterly report and detailed from time to time in the Parent's 
other filings with the Securities and Exchange Commission and the Canadian 
Securities Administrators.  Readers are cautioned not to place undue reliance 
on any of these forward-looking statements. These forward-looking statements 
speak only as of the date hereof.  The Company and Parent undertake no 
obligation to update any of these forward-looking statements to reflect events 
or circumstances after the date of this press release or to reflect actual 
outcomes. 
(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO) 
Contact Information:  Laurie W. Little  949-461-6002  laurie.little@valeant.com 
http://www.valeant.com 
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO 
PRN Photo Desk, photodesk@prnewswire.com 
SOURCE: Valeant Pharmaceuticals International, Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/March2013/29/c9500.html 
CO: Valeant Pharmaceuticals International, Inc.
NI: HEA MTC LOAN MNA  
-0- Mar/29/2013 21:30 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.